These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26129970)

  • 1. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.
    Gish RG; Yuen MF; Chan HL; Given BD; Lai CL; Locarnini SA; Lau JY; Wooddell CI; Schluep T; Lewis DL
    Antiviral Res; 2015 Sep; 121():97-108. PubMed ID: 26129970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference as a novel treatment strategy for chronic hepatitis B infection.
    Hui RW; Mak LY; Seto WK; Yuen MF
    Clin Mol Hepatol; 2022 Jul; 28(3):408-424. PubMed ID: 35172540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.
    Yuen MF; Schiefke I; Yoon JH; Ahn SH; Heo J; Kim JH; Lik Yuen Chan H; Yoon KT; Klinker H; Manns M; Petersen J; Schluep T; Hamilton J; Given BD; Ferrari C; Lai CL; Locarnini SA; Gish RG
    Hepatology; 2020 Jul; 72(1):19-31. PubMed ID: 31654573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
    Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
    Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.
    Hui RW; Mak LY; Seto WK; Yuen MF
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):127-140. PubMed ID: 35511483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.
    Gish RG; Given BD; Lai CL; Locarnini SA; Lau JY; Lewis DL; Schluep T
    Antiviral Res; 2015 Sep; 121():47-58. PubMed ID: 26092643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection.
    Wooddell CI; Rozema DB; Hossbach M; John M; Hamilton HL; Chu Q; Hegge JO; Klein JJ; Wakefield DH; Oropeza CE; Deckert J; Roehl I; Jahn-Hofmann K; Hadwiger P; Vornlocher HP; McLachlan A; Lewis DL
    Mol Ther; 2013 May; 21(5):973-85. PubMed ID: 23439496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel orally available small molecule that inhibits hepatitis B virus expression.
    Mueller H; Wildum S; Luangsay S; Walther J; Lopez A; Tropberger P; Ottaviani G; Lu W; Parrott NJ; Zhang JD; Schmucki R; Racek T; Hoflack JC; Kueng E; Point F; Zhou X; Steiner G; Lütgehetmann M; Rapp G; Volz T; Dandri M; Yang S; Young JAT; Javanbakht H
    J Hepatol; 2018 Mar; 68(3):412-420. PubMed ID: 29079285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection.
    Thi EP; Dhillon AP; Ardzinski A; Bidirici-Ertekin L; Cobarrubias KD; Cuconati A; Kondratowicz AS; Kwak K; Li AHL; Miller A; Pasetka C; Pei L; Phelps JR; Snead NM; Wang X; Ye X; Sofia MJ; Lee ACH
    ACS Infect Dis; 2019 May; 5(5):725-737. PubMed ID: 30403127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance.
    Qiu K; Liu B; Li SY; Li H; Chen ZW; Luo AR; Peng ML; Ren H; Hu P
    Aliment Pharmacol Ther; 2018 May; 47(10):1340-1348. PubMed ID: 29577360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss.
    Zimmer CL; Rinker F; Höner Zu Siederdissen C; Manns MP; Wedemeyer H; Cornberg M; Björkström NK
    J Infect Dis; 2018 Apr; 217(10):1656-1666. PubMed ID: 29471497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies.
    Wooddell CI; Gehring AJ; Yuen MF; Given BD
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33808298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.